Phenobarbital 22 mg/mL Oral Syrup is a concentrated liquid formulation designed to provide an effective and palatable means of administering phenobarbital, particularly for patients who have difficulty swallowing tablets or capsules. This includes pediatric patients, elderly patients, or those with certain medical conditions that impede swallowing.

Phenobarbital is a long-acting barbiturate commonly used as an anticonvulsant for the management and prevention of seizures. It works by decreasing abnormal electrical activity in the brain, thereby reducing the frequency and severity of seizures. This medication is particularly effective in controlling generalized tonic-clonic (grand mal) seizures, partial seizures, and febrile seizures in children.

The oral syrup formulation allows for precise dosing adjustments necessary for optimal seizure control, especially in pediatric patients where weight-based dosing is critical. The liquid form enables caregivers and healthcare providers to administer the exact dose required, enhancing therapeutic efficacy and minimizing the risk of side effects associated with improper dosing.

For prescribers, Phenobarbital 22 mg/mL Oral Syrup offers flexibility in dosing regimens and ease of administration. It facilitates individualized treatment plans for patients who require specific dosage adjustments or those who are unable to tolerate solid dosage forms. The syrup is compounded to ensure stability and bioavailability of the active ingredient while incorporating sweeteners to improve taste and adherence to the medication regimen.

Patients and caregivers should be aware of the importance of adhering strictly to the prescribed dosing schedule to maintain consistent blood levels of phenobarbital, which is crucial for effective seizure control. Regular monitoring by healthcare professionals is recommended to adjust dosing as needed and to monitor for potential side effects, such as drowsiness, dizziness, or changes in mood or behavior.

It is essential to inform the healthcare provider of any other medications being taken, as phenobarbital can interact with various drugs, potentially altering their effectiveness or increasing the risk of adverse effects. Additionally, abrupt discontinuation of phenobarbital should be avoided due to the risk of withdrawal symptoms and increased seizure activity; any changes in therapy should be conducted under medical supervision.

This compounded oral syrup provides an accessible and effective option for seizure management, supporting better compliance and quality of life for patients requiring phenobarbital therapy. If you have any questions or need further information about Phenobarbital 22 mg/mL Oral Syrup, please reach out to us

Phenobarbital is a barbiturate commonly used as an anticonvulsant to manage seizure disorders, including epilepsy, and to provide sedation. When considering the use of Phenobarbital 22 mg/mL Oral Syrup, it is crucial to be aware of potential drug interactions that may affect its efficacy and safety. This formulation is particularly beneficial for pediatric patients or those who have difficulty swallowing tablets or capsules, offering a palatable and easy-to-administer option.

Phenobarbital is a potent inducer of hepatic cytochrome P450 enzymes, particularly CYP3A4, CYP2C9, and CYP2C19. This induction can lead to decreased plasma concentrations and reduced efficacy of medications metabolized by these enzymes. For instance, oral contraceptives may become less effective, increasing the risk of unintended pregnancy. Similarly, the metabolism of anticoagulants like warfarin may be accelerated, necessitating close monitoring of INR levels and potential dose adjustments.

Concomitant use of Phenobarbital with other central nervous system (CNS) depressants, such as benzodiazepines, opioids, or alcohol, can result in additive CNS depression. This may lead to enhanced sedation, respiratory depression, and even coma, particularly in sensitive populations such as the elderly or those with compromised respiratory function. Patients should be advised to avoid alcohol and use caution when taking other CNS depressants.

Phenobarbital may also interact with other antiepileptic drugs (AEDs). For example, it can decrease the plasma levels of phenytoin and valproic acid, potentially leading to subtherapeutic levels and breakthrough seizures. Conversely, valproic acid can increase phenobarbital levels, raising the risk of toxicity. Regular monitoring of drug levels and clinical response is recommended when these medications are used together.

Additionally, phenobarbital can affect the metabolism of certain antibiotics, such as doxycycline, reducing their effectiveness. Patients should be monitored for signs of infection and alternative antibiotics may be considered if necessary. The interaction with corticosteroids may also lead to reduced efficacy, requiring dose adjustments based on clinical response.

Patients and prescribers should be aware of these potential interactions and manage them appropriately through careful monitoring and dose adjustments. It is essential to maintain open communication with healthcare providers to ensure safe and effective use of Phenobarbital 22 mg/mL Oral Syrup. If you have any questions or need further information, please reach out to us at Bayview Pharmacy.

Phenobarbital 22 mg/mL Oral Syrup is a specialized compounded formulation designed to deliver the anticonvulsant and sedative properties of phenobarbital in a liquid form. This formulation is particularly beneficial for patients who have difficulty swallowing tablets or capsules, such as pediatric patients or those with certain medical conditions that impair swallowing. The syrup is carefully compounded to ensure accurate dosing and ease of administration, making it a practical choice for managing conditions like epilepsy and other seizure disorders.

Phenobarbital works by enhancing the activity of gamma-aminobutyric acid (GABA), a neurotransmitter in the brain that inhibits nerve transmission, thereby exerting a calming effect on the nervous system. This action helps to stabilize electrical activity in the brain, reducing the frequency and severity of seizures. By providing phenobarbital in a liquid form, the syrup allows for precise dose adjustments, which is crucial in tailoring treatment to the individual needs of patients, especially in pediatric care where weight-based dosing is often required.

The formulation includes sweeteners to improve palatability, which is an important consideration for ensuring compliance, particularly in children. The sweeteners mask the bitter taste of phenobarbital, making the medication more acceptable to patients who might otherwise refuse or struggle with taking their medication. This aspect of the formulation is critical in maintaining consistent therapeutic levels of the drug, which is essential for effective seizure control.

For prescribers, the phenobarbital oral syrup offers flexibility in dosing and administration, allowing for titration to the optimal therapeutic dose with ease. This is particularly advantageous in managing complex cases where standard tablet or capsule forms may not provide the necessary dosing precision. Additionally, the liquid form can be administered via feeding tubes if necessary, further broadening its applicability in diverse clinical scenarios.

Patients and caregivers should be aware of the importance of adhering to the prescribed dosing schedule and should be instructed on how to measure the syrup accurately using a dosing syringe or cup. It is also important to monitor for potential side effects, such as drowsiness, dizziness, or changes in mood or behavior, and to report these to the healthcare provider promptly.

If you have any questions about Phenobarbital 22 mg/mL Oral Syrup or its use in treating seizure disorders, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide you with the information and support you need to ensure safe and effective use of this medication.

Phenobarbital 22 mg/mL Oral Syrup is a versatile formulation that extends its utility beyond its primary indication for seizure disorders. This concentrated liquid formulation is particularly beneficial for patients who require precise dosing adjustments, such as those with hepatic or renal impairments, where careful titration is necessary to avoid toxicity. The syrup form allows for easy administration and dose customization, which is crucial in managing conditions that require fine-tuning of medication levels.

In addition to its anticonvulsant properties, phenobarbital has been used off-label for the management of certain types of anxiety disorders, particularly in patients who have not responded well to other treatments. Its sedative effects can be beneficial in acute anxiety episodes, providing a calming effect that can help stabilize patients. Furthermore, phenobarbital has been utilized in the management of alcohol withdrawal syndrome, where its ability to mitigate withdrawal symptoms can be life-saving. The syrup formulation is especially advantageous in these scenarios, as it allows for rapid absorption and onset of action, which is critical in acute settings.

For pediatric patients, phenobarbital syrup offers a palatable and easily administered option, which is essential for ensuring adherence to treatment regimens. Children with neurological disorders that require long-term phenobarbital therapy can benefit from the syrup's ease of administration, as it can be mixed with food or beverages to mask the taste, making it more acceptable for young patients. Additionally, the syrup form is ideal for patients with feeding tubes, as it can be administered directly through the tube without the need for crushing tablets, which can alter the medication's efficacy.

Prescribers should be aware of the potential for drug interactions with phenobarbital, as it is a potent inducer of hepatic enzymes and can affect the metabolism of other medications. Regular monitoring of drug levels and patient response is recommended to ensure therapeutic efficacy and minimize adverse effects. Patients and caregivers should be educated on the importance of adherence to prescribed dosing schedules and the potential side effects of phenobarbital, such as drowsiness, dizziness, and potential dependency with long-term use.

If you have any questions or require further information about the use of Phenobarbital 22 mg/mL Oral Syrup, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to assist you with any inquiries or concerns you may have regarding this formulation.